Abstract
Effective therapeutic options have not existed for prostate cancer progressing after androgen deprivation therapy until very recently. Docetaxel based chemotherapy has been demonstrated to extend survival in 2 large randomized trials. These studies have provided the impetus to combine docetaxel with novel biologic agents to further consolidate the gains in long-term outcome. With the arrival of exciting agents including vaccines, monoclonal antibodies, bone-targeted drugs, antisense oligonucleotides, antiangiogenic drugs, and small molecule receptor tyrosine kinase inhibitors, the future of prostate cancer therapy appears promising.
MeSH terms
-
Androgen Antagonists / pharmacology*
-
Angiogenesis Inhibitors / therapeutic use
-
Antibodies, Monoclonal / therapeutic use
-
Antineoplastic Agents, Phytogenic / therapeutic use*
-
Cancer Vaccines
-
Docetaxel
-
Drug Resistance, Neoplasm
-
Enzyme Inhibitors / therapeutic use
-
Growth Inhibitors / therapeutic use
-
Humans
-
Male
-
Oligonucleotides, Antisense / therapeutic use
-
Prostatic Neoplasms / drug therapy*
-
Prostatic Neoplasms / pathology
-
Proteasome Inhibitors
-
Taxoids / therapeutic use
Substances
-
Androgen Antagonists
-
Angiogenesis Inhibitors
-
Antibodies, Monoclonal
-
Antineoplastic Agents, Phytogenic
-
Cancer Vaccines
-
Enzyme Inhibitors
-
Growth Inhibitors
-
Oligonucleotides, Antisense
-
Proteasome Inhibitors
-
Taxoids
-
Docetaxel